Evidence map›Paper›PMID 42737753›Full record

ReviewInternational journal of molecular sciences2026

Linking In Vivo Imaging to Therapeutic Outcome with

Yulia Finogenova, Alexey Lipengolts, Olga Klementyeva, Kristina Shpakova, Vsevolod Skribitsky, Elena Grigorieva

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yulia FinogenovaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0002-5144-1039
Alexey LipengoltsN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Olga KlementyevaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Kristina ShpakovaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0003-0246-1794
Vsevolod SkribitskyN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0003-2942-7895
Elena GrigorievaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0001-7726-7991

Funding

The Ministry of Economic Development of the Russian Federation 139-15-2025-008
6 · The paper itself

Abstract

Nanoparticles are increasingly explored as carriers for therapeutic radionuclides in oncology, offering prolonged circulation, high payload capacity, and active targeting. Radiolabeling enables non-invasive tracking of these constructs by SPECT or PET, providing biodistribution data that are inaccessible to ex vivo organ counting. In principle, such imaging could be used to predict therapeutic outcome, but the correlation between imaging parameters and treatment efficacy remains unclear. In this review, we analyze in vivo studies in which

Indexed as

Iodine RadioisotopesLutetiumNanoparticlesNeoplasmsRadioisotopesRadiopharmaceuticalsRheniumAnimalsHumansPositron-Emission TomographyTheranostic NanomedicineTissue DistributionTomography, Emission-Computed, Single-PhotonIodine-131Iodine RadioisotopesLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsRheniumRhenium-188combination therapyiodine-131lutetium-177nanoparticlespreclinical studiesradionuclide therapyrhenium-188SPECT imagingtheranosticstumor targeting

Identifiers

PMID42737753
PMCPMC13566003

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.